GSK3862995B for bronchiectasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Oct 2025: Trial registered, NCT07201051
  2. 30 Oct 2025: Trial started, NCT07201051

The trials

NCT07201051: A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

State
Under way
Phase
Phase 2
People
363 planned
Started
30 Oct 2025
Primary completion
4 May 2027
Arms
GSK3862995B Dose Level 1, GSK3862995B Dose Level 2
Results
None posted
  1. 1 Oct 2025: Trial registered
  2. 30 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.